乳腺癌中PGRMC1表达与临床病理参数的相关性

doi:10.3969/j.issn.1006-7795.2022.03.004

首都医科大学学报 ›› 2022, Vol. 43 ›› Issue (3): 350-356.doi: 10.3969/j.issn.1006-7795.2022.03.004

• 更年期妇科内分泌与生育力保护 • 上一篇下一篇

乳腺癌中PGRMC1表达与临床病理参数的相关性

赵越, 阮祥燕^*, 程姣姣, 谷牧青, 许新, 王月姣

首都医科大学附属北京妇产医院/北京妇幼保健院内分泌科,北京 100026

收稿日期:2022-02-27 出版日期:2022-06-21 发布日期:2022-06-01
基金资助:
北京市教育委员会科技发展计划一般项目(KM202010025009),北京市医院管理中心“青苗”计划专项经费资助(QML20181401),国家自然科学基金(81671411)。

Breast cancer pathological diagnosis reveals correlation between progesterone receptor membrane component 1 and clinicopathological parameters

Zhao Yue, Ruan Xiangyan^*, Cheng Jiaojiao, Gu Muqing, Xu Xin, Wang Yuejiao

Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing 100026, China

Received:2022-02-27 Online:2022-06-21 Published:2022-06-01
Contact: *E-mail:ruanxiangyan@ccmu.edu.cn
Supported by:
Scientific Research Common Program of Beijing Municipal Commission of Education (KM202010025009), Beijing Municipal Administration of Hospital' Youth Programme (QML20181401),National Natural Science Foundation of China (81671411).

摘要/Abstract

摘要： 目的探究孕激素受体膜组分1 (progesterone receptor membrane component 1, PGRMC1)与乳腺癌恶性增殖间的相关性。方法纳入2017年9月至2019年1月本院乳腺外科收治的乳腺癌患者90例,年龄中位数为47岁,乳腺良性疾病患者60例,年龄中位数为45岁。患者均为女性,所有组织均在术前经空心针活检或经术后病理组织学检查确诊且自愿签署知情同意书。术后取病理组织,采用苏木精-伊红染色法判断乳腺癌组织病理分级,免疫组化法分别检测乳腺癌组织、乳腺良性疾病组织及乳腺良性疾病周围1 cm正常乳腺组织中雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor, PR)、人表皮生长因子受体2(human epidermal growth factor receptor 2, Her-2)、细胞增殖核抗原(nuclear-associated antigen, Ki-67)及PGRMC1的表达水平,分析PGRMC1与相关病理因素及与其他免疫指标的相关性。结果乳腺癌组织中PGRMC1的阳性表达率为63.33%(57/90),乳腺良性疾病组织中的阳性表达率为28.33%(17/60),正常对照组织中PGRMC1阳性表达率仅为6.67%(4/60)。肿瘤直径大、有淋巴结转移、组织学分级高的乳腺癌患者,PGRMC1阳性表达率升高,组间比较差异有统计学意义(P<0.05),而与患者的月经情况无关(P>0.05)。乳腺癌组织中PGRMC1表达与ER、Ki-67、PR、Her-2的表达均有关系(P<0.05),其中与ER的关系最为密切(r=0.461),其次是Ki-67(r=0.330),而与PR、Her-2表达的关系较弱(分别为r=0.132,r=0.103)。乳腺良性疾病组织中PGRMC1表达与Ki-67及Her-2表达有关(P<0.05),其中与Ki-67(r=0.569)表达相关程度大于Her-2(r=0.228)表达。结论 PGRMC1在乳腺癌组织中高表达,并与乳腺癌淋巴结转移、肿瘤大小及组织学分级相关,可能在与激素相关肿瘤的恶性增殖及预后中有重要的临床意义,同时发现乳腺癌组织中PGRMC1与ER表达密切相关,这也进一步提示高表达PGRMC1促乳腺癌细胞增殖可能与调控ER信号通路相关。

关键词: 绝经激素治疗, 孕激素受体膜组分1, 乳腺癌, 乳腺良性疾病, 免疫组织化学

Abstract: Objective To explore the correlation between progesterone receptor membrane component 1 (PGRMC1) and malignant proliferation of breast cancer. Methods The expression of PGRMC1 was detected immunohistochemically in 90 specimens of breast cancer (the median age was 47), 60 benign breast diseases (the median age was 45) and 60 cases of normal breast tissues from September 2017 to January 2019. All of them were women, and all tissues were diagnosed by the hollow needle biopsy or postoperative histologic examination. As a research project, all participants signed informed consent voluntarily.The pathological grade of breast cancer was determined viahematoxylin-eosin staining to determine. The association of PGRMC1 with pathological factors and the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2), nuclear-associated antigen (Ki-67) was assessed. Results Positive expression of PGRMC1 was 63.33% (57/90) in breast cancer, 28.33% (17/60) in benign breast diseases and 6.67% (4/60) in normal breast tissues. PGRMC1 expression was significantly correlated to tumor size, lymphatic metastasis and the histological grade (P<0.001, respectively), PGRMC1 positive expression rate increased with the increase of histological grade of breast cancer, but not significantly correlated with menstruation in breast cancer (P>0.05). The expression of PGRMC1 in breast cancer group was related to the expression of ER, Ki-67, PR and Her-2 (P<0.05), which was most closely related to ER (r=0.461), followed by Ki-67 (r=0.330), but weakly correlated with the expression of PR and Ki-67(r=0.132,r=0.103, respectively). The expression of PGRMC1 in benign breast disease group was related to the expression of Ki-67 and Her-2 (P<0.05), and the correlation with the expression of Ki-67 (r=0.569) was higher than that of Her-2 (r=0.228). Conclusion PGRMC1 is highly expressed in breast cancer. PGRMC1 expression is strongly associated with the biological behavior of breast cancer. It may serve as a useful prognostic indicator of the malignancy. Meanwhile, it is found that PGRMC1 is closely related to ER expression in breast cancer, suggesting that PGRMC1 may potentiate estrogen signaling.

Key words: menopausal hormone therapy, progesterone receptor membrane component 1, breast cancer, benign breast diseases, immunohistochemistry

中图分类号:

R737.9

赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.

Zhao Yue, Ruan Xiangyan, Cheng Jiaojiao, Gu Muqing, Xu Xin, Wang Yuejiao. Breast cancer pathological diagnosis reveals correlation between progesterone receptor membrane component 1 and clinicopathological parameters[J]. Journal of Capital Medical University, 2022, 43(3): 350-356.

参考文献

[1] Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?[J]. Osteoporos Int, 2020, 31(12): 2271-2286.
[2] Yong E L, Logan S. Menopausal osteoporosis: screening, prevention and treatment[J]. Singapore Med J, 2021, 62(4): 159-166.
[3] Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence[J]. Lancet, 2019, 394(10204): 1159-1168.
[4] Cao M M, Li H, Sun D Q, et al. Cancer burden of major cancers in China: a need for sustainable actions[J]. Cancer Commun (Lond), 2020, 40(5): 205-210.
[5] Wei Y X, Lv J, Guo Y, et al. Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose-response meta-analysis[J]. Eur J Epidemiol, 2020, 35(6): 567-578.
[6] Sopik V. International variation in breast cancer incidence and mortality in young women[J]. Breast Cancer Res Treat, 2021, 186(2): 497-507.
[7] Zhao Y, Ruan X Y. Identification of PGRMC1 as a candidate oncogene for head and neck cancers and its involvement in metabolic activities[J]. Front Bioeng Biotechnol, 2019, 7: 438.
[8] 赵越, 阮祥燕, 张泉东, 等. 乳腺癌患者血液中PGRMC1浓度与临床相关性[J]. 首都医科大学学报, 2018, 39(4): 486-493.
[9] 赵越, 程姣姣. 孕激素受体膜组分1对激素诱导下乳腺癌增殖影响的实验研究[J]. 中国医药导报, 2019, 16(34): 11-14, 182.
[10] Zhao Y, Ruan X Y, Wang H S, et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: a xenograft model[J]. Maturitas, 2017, 102: 26-33.
[11] Finkelman B S, Meindl A, LaBoy C, et al. Correlation of manual semi-quantitative and automated quantitative Ki-67 proliferative index with OncotypeDX^TM recurrence score in invasive breast carcinoma[J]. Breast Dis, 2022, 41(1): 55-65.
[12] Teichgraeber D C, Guirguis M S, Whitman G J. Breast cancer staging: updates in the AJCC Cancer Staging Manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging[J]. AJR Am J Roentgenol, 2021, 217(2): 278-290.
[13] Tan P H, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast[J]. Histopathology, 2020, 77(2): 181-185.
[14] Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors-review of the literature[J]. Pathol Oncol Res, 2020, 26(1): 63-78.
[15] Santen R J, Heitjan D F, Gompel A, et al. Underlying breast cancer risk and menopausal hormone therapy[J]. J Clin Endocrinol Metab, 2020, 105(6): dgaa073.
[16] Ramchand S K, Cheung Y M, Yeo B, et al. The effects of adjuvant endocrine therapy on bone health in women with breast cancer[J]. J Endocrinol, 2019, 241(3): R111-R124.
[17] Li X, Ruan X, Gu M, et al. PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol[J]. Climacteric, 2019, 22(5): 483-488.
[18] Ruan X Y, Gu M Q, Cai G J, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: an in-vitro and xenograft study[J]. Maturitas, 2019, 123: 1-8.
[19] Rüschoff J, Nagelmeier I, Jasani B, et al. ISH-based HER2 diagnostics[J]. Pathologe, 2021, 42(Suppl 1): 62-68.

乳腺癌中PGRMC1表达与临床病理参数的相关性

Breast cancer pathological diagnosis reveals correlation between progesterone receptor membrane component 1 and clinicopathological parameters

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李颖, 陈彪, 王乃利, 郝欣平. 人体内耳冰冻切片免疫组织化学染色技术探讨[J]. 首都医科大学学报, 2022, 43(6): 905-910.
[2]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[3]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[4]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[5]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.
[6]	吴西抗, 王跃, 贺慧颖. 上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系[J]. 首都医科大学学报, 2020, 41(3): 354-359.
[7]	高巍, 赵莉红, 王玮, 王雷明, 许素素, 隗立峰, 滕梁红. 基于WHO新分类的垂体腺瘤诊断及临床病理分析[J]. 首都医科大学学报, 2020, 41(3): 364-371.
[8]	王爱婷, 鄢丹, 齐宪荣. 包载多西他赛的聚合物胶束抑制小鼠乳腺癌转移作用研究[J]. 首都医科大学学报, 2020, 41(2): 225-230.
[9]	王维, 张紫寒, 翟妍, 桑翠琴, 王淑珍. 子宫体、乳腺双原发癌的临床病理特征[J]. 首都医科大学学报, 2019, 40(6): 857-862.
[10]	张蕴显, 王雅梅, 周萍. 乳腺癌中基于开放染色质的环状RNA互作网络构建及功能分析[J]. 首都医科大学学报, 2019, 40(6): 901-910.
[11]	白向东, 郝雅婷, 张欣雪, 贺强. 脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究[J]. 首都医科大学学报, 2019, 40(6): 911-915.
[12]	张凌燕, 阮祥燕, 蔡桂举, 谷牧青, Alfred O. Mueck. 他莫昔芬治疗转染孕激素受体膜组分1乳腺癌裸鼠模型对乳腺肿瘤组织Ki-67表达的影响[J]. 首都医科大学学报, 2019, 40(4): 533-538.
[13]	王月姣, 阮祥燕, 谷牧青, 蔡桂举, 李雪, 张凌燕, Alfred O. Mueck. 他莫昔芬治疗乳腺癌异种移植瘤裸鼠子宫病理改变[J]. 首都医科大学学报, 2019, 40(4): 539-543.
[14]	白向东, 郝雅婷, 张欣雪, 贺强. 雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察[J]. 首都医科大学学报, 2019, 40(3): 443-448.
[15]	陈妮娜, 范怡畅, 尚昆, 杨婧, 曹邦伟. 血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究[J]. 首都医科大学学报, 2019, 40(2): 191-194.